Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015 (2015), Article ID 825670, 4 pages
http://dx.doi.org/10.1155/2015/825670
Case Report

Nelarabine Associated Myotoxicity and Rhabdomyolysis

Division of Internal Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA

Received 18 January 2015; Accepted 14 March 2015

Academic Editor: Ray Lowenthal

Copyright © 2015 Mahnur Haider et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. H. Cohen, J. R. Johnson, R. Justice, and R. Pazdur, “FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma,” Oncologist, vol. 13, no. 6, pp. 709–714, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. DeAngelo, “Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma,” Hematology/Oncology Clinics of North America, vol. 23, no. 5, pp. 1121–1135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Zimmerman and M. C. Shen, “Rhabdomyolysis,” Chest, vol. 144, no. 3, pp. 1058–1065, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. K. M. Reilly and D. F. Kisor, “Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia,” OncoTargets and Therapy, vol. 2, pp. 219–228, 2009. View at Google Scholar · View at Scopus
  5. D. Ngo, S. Patel, E. J. Kim, R. Brar, and M. Z. Koontz, “Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: case report and review of literature,” Journal of Oncology Pharmacy Practice, 2014. View at Publisher · View at Google Scholar
  6. M. Czuczman, P. Porcu, J. Johnson et al., “Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901,” Leukemia & Lymphoma, vol. 48, no. 1, pp. 97–103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Forcade, T. Leguay, N. Vey et al., “Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival,” Biology of Blood and Marrow Transplantation, vol. 19, no. 7, pp. 1124–1126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. K. P. Dunsmore, M. Devidas, S. B. Linda et al., “Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2753–2759, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Robak and T. Robak, “Older and new purine nucleoside analogs for patients with acute leukemias,” Cancer Treatment Reviews, vol. 39, no. 8, pp. 851–861, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Roecker, A. Stockert, and D. F. Kisor, “Nelarabine in the treatment of refractory T-Cell malignancies,” Clinical Medicine Insights: Oncology, vol. 4, pp. 133–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Patrick and A. Vora, “Update on biology and treatment of T-cell acute lymphoblastic leukaemia,” Current Opinion in Pediatrics, vol. 27, no. 1, pp. 44–49, 2015. View at Publisher · View at Google Scholar
  12. Inc, G: Product Monograph: Nelarabine (Arranon) 2015, (2014).
  13. N. Gökbuget, N. Basara, H. Baurmann et al., “High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation,” Blood, vol. 118, no. 13, pp. 3504–3511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. Commander, A. E. Seif, I. G. Insogna, and S. R. Rheingold, “Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma,” British Journal of Haematology, vol. 150, no. 3, pp. 345–351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Gandhi, W. Plunkett, C. O. Rodriguez Jr. et al., “Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3607–3615, 1998. View at Google Scholar · View at Scopus
  16. D. J. DeAngelo, D. Yu, J. L. Johnson et al., “Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801,” Blood, vol. 109, no. 12, pp. 5136–5142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. H. Cohen, J. R. Johnson, T. Massie et al., “Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma,” Clinical Cancer Research, vol. 12, no. 18, pp. 5329–5335, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. L. Berg, S. M. Blaney, M. Devidas et al., “Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3376–3382, 2005. View at Publisher · View at Google Scholar · View at Scopus